Show simple item record

dc.contributor.authorVuong, Nguyen Lam
dc.contributor.authorLe Duyen, Huynh Thi
dc.contributor.authorLam, Phung Khanh
dc.contributor.authorTam, Dong Thi Hoai
dc.contributor.authorVinh Chau, Nguyen Van
dc.contributor.authorVan Kinh, Nguyen
dc.contributor.authorChanpheaktra, Ngoun
dc.contributor.authorLum, Lucy Chai See
dc.contributor.authorPleités, Ernesto
dc.contributor.authorJones, Nick Keith
dc.contributor.authorSimmons, Cameron Paul
dc.contributor.authorRosenberger, Kerstin
dc.contributor.authorJaenisch, Thomas
dc.contributor.authorHalleux, Christine
dc.contributor.authorOlliaro, Piero Luigi
dc.contributor.authorWills, Bridget
dc.contributor.authorYacoub, Sophie
dc.date.accessioned2021-02-16T16:18:50Z
dc.date.available2021-02-16T16:18:50Z
dc.date.issued2020-02-17
dc.date.submitted2019-08-08
dc.identifier.others12916-020-1496-1
dc.identifier.other1496
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/317740
dc.description.abstractAbstract: Background: Dengue infection can cause a wide spectrum of clinical outcomes. The severe clinical manifestations occur sufficiently late in the disease course, during day 4–6 of illness, to allow a window of opportunity for risk stratification. Markers of inflammation may be useful biomarkers. We investigated the value of C-reactive protein (CRP) measured early on illness days 1–3 to predict dengue disease outcome and the difference in CRP levels between dengue and other febrile illnesses (OFI). Method: We performed a nested case-control study using the clinical data and samples collected from the IDAMS-consortium multi-country study. This was a prospective multi-center observational study that enrolled almost 8000 participants presenting with a dengue-like illness to outpatient facilities in 8 countries across Asia and Latin America. Predefined severity definitions of severe and intermediate dengue were used as the primary outcomes. A total of 281 cases with severe/intermediate dengue were compared to 836 uncomplicated dengue patients as controls (ratio 1:3), and also 394 patients with OFI. Results: In patients with confirmed dengue, median (interquartile range) of CRP level within the first 3 days was 30.2 mg/L (12.4–61.2 mg/L) (uncomplicated dengue, 28.6 (10.5–58.9); severe or intermediate dengue, 34.0 (17.4–71.8)). Higher CRP levels in the first 3 days of illness were associated with a higher risk of severe or intermediate outcome (OR 1.17, 95% CI 1.07–1.29), especially in children. Higher CRP levels, exceeding 30 mg/L, also associated with hospitalization (OR 1.37, 95% CI 1.14–1.64) and longer fever clearance time (HR 0.84, 95% CI 0.76–0.93), especially in adults. CRP levels in patients with dengue were higher than patients with potential viral infection but lower than patients with potential bacterial infection, resulting in a quadratic association between dengue diagnosis and CRP, with levels of approximately 30 mg/L associated with the highest risk of having dengue. CRP had a positive correlation with total white cell count and neutrophils and negative correlation with lymphocytes, but did not correlate with liver transaminases, albumin, or platelet nadir. Conclusions: In summary, CRP measured in the first 3 days of illness could be a useful biomarker for early dengue risk prediction and may assist differentiating dengue from other febrile illnesses.
dc.languageen
dc.publisherBioMed Central
dc.rightsAttribution 4.0 International (CC BY 4.0)en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectResearch Article
dc.subjectDengue
dc.subjectBiomarker
dc.subjectC-reactive protein
dc.subjectPrognosis
dc.subjectOther febrile illness
dc.titleC-reactive protein as a potential biomarker for disease progression in dengue: a multi-country observational study
dc.typeArticle
dc.date.updated2021-02-16T16:18:49Z
prism.issueIdentifier1
prism.publicationNameBMC Medicine
prism.volume18
dc.identifier.doi10.17863/CAM.64854
dcterms.dateAccepted2020-01-13
rioxxterms.versionofrecord10.1186/s12916-020-1496-1
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidYacoub, Sophie [0000-0002-2910-7819]
dc.identifier.eissn1741-7015
pubs.funder-project-idWorld Health Organization (UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases)
pubs.funder-project-idEuropean Union (FP7-281803 IDAMS)


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's licence is described as Attribution 4.0 International (CC BY 4.0)